Clinical Aspects of Hemochromatosis

ABSTRACT

The term hemochromatosis is commonly used as synonymous with HFE-associated genetic iron overload but several rarer causes of an identical clinicopathological syndrome have been described in recent years. The most common symptoms are lethargy and arthralgia, and the major complications of end-stage disease are cirrhosis, diabetes, and cardiac and endocrine manifestations. However, with the development of cascade screening for family members of affected probands as well as screening for common diseases at health checks, hemochromatosis is being detected at increasingly early stages, often when there are only biochemical abnormalities.

The available evidence from screening studies strongly suggests that ~75% of C282Y homozygous subjects have biochemical expression. Hepatic iron overload is present in ~56% and 34% of men and women, respectively, advanced hepatic fibrosis in 18.7% and 5.4%, respectively, and cirrhosis in 5.8% and 1.9%, respectively. In subjects with severe expression of the disease, additional modifying genetic mutations have been described including those in hepcidin and hemojuvelin. Treatment is by regular phlebotomy which, if instituted before the development of cirrhosis, results in normal life expectancy.

Hemochromatosis - iron overload - iron metabolism

REFERENCES

• 1 von Recklinghausen F. Taggeblet de.  Versainumlung Deutsch Naturforsch Arzt Heidelberg. 1889;  62 324-325
• 2 Bacon B R, Powell L W, Adams P C, Kresina T F, Hoofnagle J H. Molecular medicine and hemochromatosis: at the crossroads.  Gastroenterology. 1999;  116 193-207
• 3 Adams P C. Hemochromatosis.  Clin Liver Dis. 2004;  8 735-753, vii
• 4 Sheldon J. Haemochromatosis. London, England; Oxford University Press 1935: 339
• 5 Finch S C, Finch C A. Idiopathic hemochromatosis:an iron storage disease.  Medicine. 1955;  34 381-430
• 6 Pietrangelo A. Hereditary hemochromatosis-a new look at an old disease.  N Engl J Med. 2004;  350 2383-2397
• 7 Feder J N, Gnirke A, Thomas W et al.. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis.  Nat Genet. 1996;  13 399-408
• 8 Adams P, Brissot P, Powell L W. EASL International Consensus Conference on Haemochromatosis.  J Hepatol. 2000;  33 485-504
• 9 Pietrangelo A. Non-HFE-linked hemochromatosis.  Semin Liver Dis. 2005;  25 450-460
• 10 Bulaj Z J, Ajioka R S, Phillips J D et al.. Disease-related conditions in relatives of patients with hemochromatosis.  N Engl J Med. 2000;  343 1529-1535
• 11 Asberg A, Hveem K, Thorstensen K et al.. Screening for hemochromatosis: high prevalence and low morbidity in an unselected population of 65,238 persons.  Scand J Gastroenterol. 2001;  36 1108-1115
• 12 Milman N, Pedersen P, Ovesen L, Melsen G V, Fenger K. Frequency of the C282Y and H63D mutations of the hemochromatosis gene (HFE) in 2501 ethnic Danes.  Ann Hematol. 2004;  83 654-657
• 13 Beutler E, Felitti V J, Koziol J A, Ho N J, Gelbart T. Penetrance of 845G-A (C282Y) HFE hereditary haemochromatosis mutation in the USA.  Lancet. 2002;  359 211-218
• 14 Adams P C, Reboussin D M, Barton J C et al.. Hemochromatosis and iron-overload screening in a racially diverse population.  N Engl J Med. 2005;  352 1769-1778
• 15 Powell L P, Dixon J L, Ramm G A et al.. The penetrance of HFE-associated hemochromatosis as assessed by clinical evaluation and liver biopsy in subjects identified by health checks, family screening or population screening.  Hepatology. 2004;  40 74A
• 16 Ajioka R S, Jorde L B, Gruen J R et al.. Haplotype analysis of hemochromatosis: evaluation of different linkage-disequilibrium approaches and evolution of disease chromosomes.  Am J Hum Genet. 1997;  60 1439-1447
• 17 Simon M. Genetics of hemochromatosis.  N Engl J Med. 1979;  301 1291-1292
• 18 Simon M, Alexandre J L, Fauchet R, Genetet B, Bourel M. The genetics of hemochromatosis.  Prog Med Genet. 1980;  4 135-168
• 19 Merryweather-Clarke A T, Pointon J J, Shearman J D, Robson K J. Global prevalence of putative haemochromatosis mutations.  J Med Genet. 1997;  34 275-278
• 20 Moirand R, Jouanolle A M, Brissot P et al.. Phenotypic expression of HFE mutations: a French study of 1110 unrelated iron-overloaded patients and relatives.  Gastroenterology. 1999;  116 372-377
• 21 Gochee P A, Powell L W, Cullen D J et al.. A population-based study of the biochemical and clinical expression of the H63D hemochromatosis mutation.  Gastroenterology. 2002;  122 646-651
• 22 Brandhagen D J, Fairbanks V F, Baldus W. Recognition and management of hereditary hemochromatosis.  Am Fam Physician. 2002;  65 853-860
• 23 Bassett M L, Halliday J W, Powell L W. Value of hepatic iron measurements in early hemochromatosis and determination of the critical iron level associated with fibrosis.  Hepatology. 1986;  6 24-29
• 24 Bassett M L, Halliday J W, Ferris R A, Powell L W. Diagnosis of hemochromatosis in young subjects: predictive accuracy of biochemical screening tests.  Gastroenterology. 1984;  87 628-633
• 25 Waalen J, Nordestgaard B G, Beutler E. The penetrance of hereditary hemochromatosis.  Best Pract Res Clin Haematol. 2005;  18 203-220
• 26 Allen K J, Delatycki M B, Nisselle A E et al.. Use of community screening to prevent HFE-associated hereditary haemochromatosis.  Lancet. 366 314-316
• 27 Niederau C, Fischer R, Purschel A et al.. Long-term survival in patients with hereditary hemochromatosis.  Gastroenterology. 1996;  110 1107-1119
• 28 Lin E, Adams P C. Biochemical liver profile in hemochromatosis. A survey of 100 patients.  J Clin Gastroenterol. 1991;  13 316-320
• 29 Olynyk J K, Cullen D J, Aquilia S et al.. A population-based study of the clinical expression of the hemochromatosis gene.  N Engl J Med. 1999;  341 718-724
• 30 Wojcik J P, Speechley M R, Kertesz A E, Chakrabarti S, Adams P C. Natural history of C282Y homozygotes for hemochromatosis.  Can J Gastroenterol. 2002;  16 297-302
• 31 Bradbear R A, Bain C, Siskind V et al.. Cohort study of internal malignancy in genetic hemochromatosis and other chronic nonalcoholic liver diseases.  J Natl Cancer Inst. 1985;  75 81-84
• 32 Adams P C, Deugnier Y, Moirand R, Brissot P. The relationship between iron overload, clinical symptoms, and age in 410 patients with genetic hemochromatosis.  Hepatology. 1997;  25 162-166
• 33 Stocks A E, Powell L W. Pituitary function in idiopathic haemochromatosis and cirrhosis of the liver.  Lancet. 1972;  2 298-300
• 34 Adams P C, Chakrabarti S. Genotypic/phenotypic correlations in genetic hemochromatosis: evolution of diagnostic criteria.  Gastroenterology. 1998;  114 319-323
• 35 Bacon B R. Hemochromatosis: diagnosis and management.  Gastroenterology. 2001;  120 718-725
• 36 Bacon B R. Diagnosis and management of hemochromatosis.  Gastroenterology. 1997;  113 995-999
• 37 Allen K, Williamson R. Screening for hereditary haemochromatosis should be implemented now.  BMJ. 2000;  320 183-184
• 38 Fletcher L M, Dixon J L, Purdie D M, Powell L W, Crawford D H. Excess alcohol greatly increases the prevalence of cirrhosis in hereditary hemochromatosis.  Gastroenterology. 2002;  122 281-289
• 39 Fletcher L M, Powell L W. Hemochromatosis and alcoholic liver disease.  Alcohol. 2003;  30 131-136
• 40 Powell L W. The role of alcoholism in hepatic iron storage disease.  Ann N Y Acad Sci. 1975;  252 124-134
• 41 Bacon B R, Sadiq S A. Hereditary hemochromatosis: presentation and diagnosis in the 1990s.  Am J Gastroenterol. 1997;  92 784-789
• 42 Tavill A S. American Association for the Study of Liver Diseases; American College of Gastroenterology; American Gastroenterological Association . Diagnosis and management of hemochromatosis.  Hepatology. 2001;  33 1321-1328
• 43 Witte D L. Mild liver enzyme abnormalities: eliminating hemochromatosis as cause.  Clin Chem. 1997;  43(8 Pt 2) 1535-1538
• 44 McLaren C E, McLachlan G J, Halliday J W et al.. Distribution of transferrin saturation in an Australian population: relevance to the early diagnosis of hemochromatosis.  Gastroenterology. 1998;  114 543-549
• 45 Edwards C Q, Kushner J P. Screening for hemochromatosis.  N Engl J Med. 1993;  328 1616-1620
• 46 Beilby J, Olynyk J, Ching S et al.. Transferrin index: an alternative method for calculating the iron saturation of transferrin.  Clin Chem. 1992;  38 2078-2081
• 47 Murtagh L J, Whiley M, Wilson S, Tran H, Bassett M L. Unsaturated iron binding capacity and transferrin saturation are equally reliable in detection of HFE hemochromatosis.  Am J Gastroenterol. 2002;  97 2093-2099
• 48 McCullen M A, Crawford D H, Dimeski G, Tate J, Hickman P E. Why there is discordance in reported decision thresholds for transferrin saturation when screening for hereditary hemochromatosis.  Hepatology. 2000;  32 1410-1411
• 49 Walters G O, Miller F M, Worwood M. Serum ferritin concentration and iron stores in normal subjects.  J Clin Pathol. 1973;  26 770-772
• 50 Morrison E D, Brandhagen D J, Phatak P D et al.. Serum ferritin level predicts advanced hepatic fibrosis among US patients with phenotypic hemochromatosis.  Ann Intern Med. 2003;  138 627-633
• 51 Beutler E, Felitti V, Gelbart T, Ho N. The effect of HFE genotypes on measurements of iron overload in patients attending a health appraisal clinic.  Ann Intern Med. 2000;  133 329-337
• 52 Di Bisceglie A M, Axiotis C A, Hoofnagle J H, Bacon B R. Measurements of iron status in patients with chronic hepatitis.  Gastroenterology. 1992;  102 2108-2113
• 53 Bacon B R, Farahvash M J, Janney C G, Neuschwander-Tetri B A. Nonalcoholic steatohepatitis: an expanded clinical entity.  Gastroenterology. 1994;  107 1103-1109
• 54 Edwards C Q, Griffen L M, Kaplan J, Kushner J P. Twenty-four hour variation of transferrin saturation in treated and untreated haemochromatosis homozygotes.  J Intern Med. 1989;  226 373-379
• 55 Chapman R W, Morgan M Y, Laulicht M, Hoffbrand A V, Sherlock S. Hepatic iron stores and markers of iron overload in alcoholics and patients with idiopathic hemochromatosis.  Dig Dis Sci. 1982;  27 909-916
• 56 Guyader D, Jacquelinet C, Moirand R et al.. Noninvasive prediction of fibrosis in C282Y homozygous hemochromatosis.  Gastroenterology. 1998;  115 929-936
• 57 Bacon B R, Olynyk J K, Brunt E M, Britton R S, Wolff R K. HFE genotype in patients with hemochromatosis and other liver diseases.  Ann Intern Med. 1999;  130 953-962
• 58 Whittington C A, Kowdley K V. Review article: haemochromatosis.  Aliment Pharmacol Ther. 2002;  16 1963-1975
• 59 Powell L W. Broadsheet number 54. Hereditary hemochromatosis.  Pathology. 2000;  32 24-36
• 60 Powell L W, Subramaniam V N, Yapp T R. Haemochromatosis in the new millennium.  J Hepatol. 2000;  32 48-62
• 61 Gandon Y, Olivie D, Guyader D et al.. Non-invasive assessment of hepatic iron stores by MRI.  Lancet. 2004;  363 357-362
• 62 Alustiza J M, Artetxe J, Castiella A et al.. MR quantification of hepatic iron concentration.  Radiology. 2004;  230 479-484
• 63 St Pierre T G, Clark P R, Chua-anusorn W et al.. Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance.  Blood. 2005;  105 855-861
• 64 Steinberg K K, Cogswell M E, Chang J C et al.. Prevalence of C282Y and H63D mutations in the hemochromatosis (HFE) gene in the United States.  JAMA. 2001;  285 2216-2222
• 65 George D K, Goldwurm S, MacDonald G A et al.. Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis.  Gastroenterology. 1998;  114 311-318
• 66 Halfon P, Imbert-Bismut F, Messous D et al.. A prospective assessment of the inter-laboratory variability of biochemical markers of fibrosis (FibroTest) and activity (ActiTest) in patients with chronic liver disease.  Comp Hepatol. 2002;  1 3
• 67 Poynard T, Imbert-Bismut F, Munteanu M, Ratziu V. FibroTest-FibroSURE: towards a universal biomarker of liver fibrosis?.  Expert Rev Mol Diagn. 2005;  5 15-21
• 68 Powell L W, Kerr J F. The pathology of the liver in hemochromatosis.  Pathobiol Annu. 1975;  5 317-337
• 69 Andersen R V, Tybjaerg-Hansen A, Appleyard M, Birgens H, Nordestgaard B G. Hemochromatosis mutations in the general population: iron overload progression rate.  Blood. 2004;  103 2914-2919
• 70 Olynyk J K, Hagan S E, Cullen D J, Beilby J, Whittall D E. Evolution of untreated hereditary hemochromatosis in the Busselton population: a 17-year study.  Mayo Clin Proc. 2004;  79 309-313
• 71 Powell E E, Cooksley W G, Hanson R, Searles J, Halliday J W, Powell L W. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years.  Hepatology. 1990;  11 74-80
• 72 Angulo P, Keach J C, Batts K P, Lindor K D. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis.  Hepatology. 1999;  30 1356-1362
• 73 Whitfield J B, Cullen L M, Jazwinska E C et al.. Effects of HFE C282Y and H63D polymorphisms and polygenic background on iron stores in a large community sample of twins.  Am J Hum Genet. 2000;  66 1246-1258
• 74 Majore S, Binni F, Pennese A, De Santis A, Crisi A, Grammatico P. HAMP gene mutation c.208T > C (p.C70R) identified in an Italian patient with severe hereditary hemochromatosis.  Hum Mutat. 2004;  23 400
• 75 Pietrangelo A, Montosi G, Totaro A et al.. Hereditary hemochromatosis in adults without pathogenic mutations in the hemochromatosis gene.  N Engl J Med. 1999;  341 725-732
• 76 Camaschella C, Roetto A, Cali A et al.. The gene TFR2 is mutated in a new type of haemochromatosis mapping to 7q22.  Nat Genet. 2000;  25 14-15
• 77 Papanikolaou G, Samuels M E, Ludwig E H et al.. Mutations in HFE2 cause iron overload in chromosome 1q-linked juvenile hemochromatosis.  Nat Genet. 2004;  36 77-82
• 78 Fleming R E, Sly W S. Hepcidin: a putative iron-regulatory hormone relevant to hereditary hemochromatosis and the anemia of chronic disease.  Proc Natl Acad Sci USA. 2001;  98 8160-8162
• 79 Nicolas G, Viatte L, Lou D Q et al.. Constitutive hepcidin expression prevents iron overload in a mouse model of hemochromatosis.  Nat Genet. 2003;  34 97-101
• 80 Nicolas G, Chauvet C, Viatte L et al.. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation.  J Clin Invest. 2002;  110 1037-1044
• 81 Ganz T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation.  Blood. 2003;  102 783-788
• 82 Fleming R E, Britton R S, Waheed A, Sly W S, Bacon B R. Pathophysiology of hereditary hemochromatosis.  Semin Liver Dis. 2005;  25 411-419
• 83 Jacolot S, Le Gac G, Scotet V et al.. HAMP as a modifier gene that increases the phenotypic expression of the HFE pC282Y homozygous genotype.  Blood. 2004;  103 2835-2840
• 84 Merryweather-Clarke A T, Cadet E, Bomford A et al.. Digenic inheritance of mutations in HAMP and HFE results in different types of haemochromatosis.  Hum Mol Genet. 2003;  12 2241-2247
• 85 Biasiotto G, Roetto A, Daraio F et al.. Identification of new mutations of hepcidin and hemojuvelin in patients with HFE C282Y allele.  Blood Cells Mol Dis. 2004;  33 338-343
• 86 Allen K, Williamson R. Should we genetically test everyone for haemochromatosis?.  J Med Ethics. 1999;  25 209-214
• 87 Ombiga J, Adams L A, Tang K, Trinder D, Olynyk J K. Screening for HFE and iron overload.  Semin Liver Dis. 2005;  25 402-410
• 88 Crawford D H, Fletcher L M, Hubscher S G et al.. Patient and graft survival after liver transplantation for hereditary hemochromatosis: implications for pathogenesis.  Hepatology. 2004;  39 1655-1662
• 89 Kowdley K V. Liver transplantation: an “in vivo” model for the pathophysiology of hemochromatosis?.  Hepatology. 2004;  39 1495-1498
• 90 Powell L W. Does transplantation of the liver cure genetic hemochromatosis?.  J Hepatol. 1992;  16 259-261
• 91 Brandhagen D J, Alvarez W, Therneau T M et al.. Iron overload in cirrhosis-HFE genotypes and outcome after liver transplantation.  Hepatology. 2000;  31 456-460
• 92 Fiel M I, Schiano T D, Bodenheimer H C et al.. Hereditary hemochromatosis in liver transplantation.  Liver Transpl Surg. 1999;  5 50-56
• 93 Kowdley K V, Hassanein T, Kaur S et al.. Primary liver cancer and survival in patients undergoing liver transplantation for hemochromatosis.  Liver Transpl Surg. 1995;  1 237-241
• 94 Farrell F J, Nguyen M, Woodley S et al.. Outcome of liver transplantation in patients with hemochromatosis.  Hepatology. 1994;  20 404-410
• 95 Bridle K R, Frazer D M, Wilkins S J et al.. Disrupted hepcidin regulation in HFE-associated haemochromatosis and the liver as a regulator of body iron homoeostasis.  Lancet. 2003;  361 669-673
• 96 Gehrke S G, Kulaksiz H, Herrmann T et al.. Expression of hepcidin in hereditary hemochromatosis: evidence for a regulation in response to the serum transferrin saturation and to non-transferrin-bound iron.  Blood. 2003;  102 371-376